REG - Creo Medical Group - Result of General Meeting & TVR

Creo MedicalAnnouncement

18/10/2024 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241018:nRSR7921Ia&default-theme=true

RNS Number : 7921I  Creo Medical Group PLC  18 October 2024

THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED
AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR
IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW
ZEALAND, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, JAPAN
OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION
WOULD BE UNLAWFUL.

 

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN
OFFER OF SECURITIES IN ANY JURISDICTION.

 

LEI: 213800H188ZDCWWXFA21

18 October 2024

Creo Medical Group plc

("Creo" or the "Company")

 

Result of General Meeting

and Total Voting Rights

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy for cancer and pre-cancer patients, is
pleased to announce that at its General Meeting held today all of the
resolutions, as set out in the Circular dated 1 October 2024, were duly
passed.

 

The voting results will be made available on the Company's website shortly at:

 

https://creomedical.com/en/investors/reports-and-presentations
(https://creomedical.com/en/investors/reports-and-presentations)

 

Application has been made for a total of 50,369,109 New Ordinary Shares, to be
issued pursuant to the Placing and Retail Offer, to be admitted to trading on
AIM. It is expected that Admission and dealings in the 50,369,109 New Ordinary
Shares will commence at 8.00 a.m. on 21 October 2024. Following Admission, the
Enlarged Share Capital of the Company will consist of 412,148,979 Ordinary
Shares. Therefore, the total number of voting rights in the Company is
412,148,979 and this figure may be used by Shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in the Company, or there is a change to their interest in the
Company.

 

This announcement should be read in conjunction with the full text of the
Circular posted to Shareholders on 1 October 2024, copies of which are
available on the Company's website www.creomedical.com/investors. The same
definitions apply throughout this announcement as are applied in the Circular.

 

For further information please contact:

 

 Creo Medical Group plc                                   www.creomedical.com (http://www.creomedical.com/)
 Richard Craven, Company Secretary                        Via Walbrook PR

 Cavendish Capital Markets Limited

 (Nominated Adviser, Joint Bookrunner and Joint Broker)   +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume / George Lawson (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Bookrunner and Joint Broker)       +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 William Baunton (ECM)

 Walbrook PR Ltd                                          Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings                            Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMEANEPFASLFEA